iRhythm Technologies (NASDAQ:IRTC) Price Target Cut to $215.00 by Analysts at JPMorgan Chase & Co.

iRhythm Technologies (NASDAQ:IRTC) had its price target reduced by JPMorgan Chase & Co. from $240.00 to $215.00 in a report released on Friday,Benzinga reports. JPMorgan Chase & Co. currently has an overweight rating on the stock.

Other equities analysts also recently issued research reports about the company. Evercore raised iRhythm Technologies from an “in-line” rating to an “outperform” rating and increased their price target for the stock from $194.00 to $210.00 in a research report on Monday, January 5th. Truist Financial set a $200.00 price objective on shares of iRhythm Technologies in a research note on Friday. Wells Fargo & Company dropped their target price on shares of iRhythm Technologies from $225.00 to $200.00 and set an “overweight” rating on the stock in a report on Friday. BTIG Research raised their target price on shares of iRhythm Technologies from $195.00 to $215.00 and gave the company a “buy” rating in a research report on Friday, October 31st. Finally, Robert W. Baird lowered their price target on shares of iRhythm Technologies from $220.00 to $200.00 and set an “outperform” rating for the company in a research report on Friday. Two equities research analysts have rated the stock with a Strong Buy rating, eleven have issued a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, iRhythm Technologies presently has an average rating of “Moderate Buy” and an average price target of $211.62.

iRhythm Technologies Price Performance

Shares of IRTC stock opened at $150.96 on Friday. The company has a market capitalization of $4.86 billion, a P/E ratio of -107.83 and a beta of 1.06. The company’s 50-day simple moving average is $164.65 and its two-hundred day simple moving average is $171.29. iRhythm Technologies has a one year low of $92.52 and a one year high of $212.00. The company has a debt-to-equity ratio of 5.32, a current ratio of 4.63 and a quick ratio of 4.50.

iRhythm Technologies (NASDAQ:IRTC) last posted its quarterly earnings results on Thursday, February 19th. The company reported $0.29 earnings per share for the quarter, beating the consensus estimate of $0.02 by $0.27. iRhythm Technologies had a negative net margin of 5.96% and a negative return on equity of 31.44%. The firm had revenue of $208.89 million during the quarter, compared to the consensus estimate of $202.61 million. During the same quarter in the previous year, the firm posted ($0.04) earnings per share. The company’s revenue was up 27.1% on a year-over-year basis. As a group, equities analysts anticipate that iRhythm Technologies will post -1.98 EPS for the current year.

Insider Buying and Selling at iRhythm Technologies

In related news, insider Chad Patterson sold 280 shares of the company’s stock in a transaction dated Tuesday, December 2nd. The stock was sold at an average price of $184.83, for a total transaction of $51,752.40. Following the transaction, the insider directly owned 43,387 shares of the company’s stock, valued at $8,019,219.21. This represents a 0.64% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this link. Also, insider Patrick Michael Murphy sold 2,478 shares of the stock in a transaction dated Tuesday, December 2nd. The shares were sold at an average price of $184.83, for a total value of $458,008.74. Following the completion of the sale, the insider owned 53,281 shares of the company’s stock, valued at approximately $9,847,927.23. This trade represents a 4.44% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Corporate insiders own 1.10% of the company’s stock.

Institutional Investors Weigh In On iRhythm Technologies

Large investors have recently modified their holdings of the business. Measured Wealth Private Client Group LLC purchased a new position in shares of iRhythm Technologies in the 3rd quarter valued at approximately $30,000. Root Financial Partners LLC acquired a new position in iRhythm Technologies during the 3rd quarter valued at approximately $30,000. GAMMA Investing LLC raised its holdings in shares of iRhythm Technologies by 48.4% in the fourth quarter. GAMMA Investing LLC now owns 184 shares of the company’s stock worth $33,000 after buying an additional 60 shares during the last quarter. Smartleaf Asset Management LLC raised its holdings in shares of iRhythm Technologies by 100.0% in the third quarter. Smartleaf Asset Management LLC now owns 198 shares of the company’s stock worth $34,000 after buying an additional 99 shares during the last quarter. Finally, FNY Investment Advisers LLC acquired a new stake in shares of iRhythm Technologies during the third quarter worth $34,000.

Key Headlines Impacting iRhythm Technologies

Here are the key news stories impacting iRhythm Technologies this week:

• Positive Sentiment: Q4 results beat estimates — Revenue $208.9M (+27.1% YoY) and EPS $0.29 topped consensus; management reported record quarterly revenue, improved gross margin and positive GAAP net income for the quarter. Globe Newswire: Q4 Results
• Positive Sentiment: Beating the street — Third‑party coverage highlights the earnings and revenue beat and improved profitability metrics (adjusted EBITDA, cash flow). These operational improvements support upside case over time. Zacks: Earnings Beat
• Neutral Sentiment: Company materials available — Earnings call transcript and slide deck published for investors to evaluate management commentary and forward drivers (AC C presentations and upcoming data cadence). Useful for confirming guidance/assumptions. Seeking Alpha: Call Transcript
• Neutral Sentiment: Market coverage noted positive market reaction after the print in some outlets — short-term sentiment can swing quickly as investors parse details. MassDevice: Market Reaction
• Negative Sentiment: Analysts trimmed price targets across several firms today (Canaccord, JPMorgan, Wells Fargo, Robert W. Baird) — ratings remain generally positive/overweight but lower targets reduce near‑term upside expectations and can pressure the stock. Benzinga: Analyst Target Changes
• Negative Sentiment: Insider selling and institutional rebalancing highlighted — multiple insider sales and large shifts in fund holdings raise concern about near-term selling pressure and supply overhang. Quiver: Insider & Institutional Activity

iRhythm Technologies Company Profile

iRhythm Technologies, Inc is a medical technology company that develops and commercializes wearable cardiac monitoring devices and associated data analytics services. Founded in 2006 and headquartered in San Francisco, California, the company’s flagship product is the Zio® patch, a discreet, single-use, continuous ECG recorder designed to monitor heart rhythms for up to 14 days. iRhythm’s digital diagnostics platform combines biosensor technology with proprietary algorithms to detect arrhythmias and streamline data interpretation for physicians.

The Zio service is prescribed by cardiologists and other healthcare providers to aid in the diagnosis of atrial fibrillation, bradycardia, tachycardia and other rhythm disorders.